These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 29316337)
41. An arginine-rich cell penetrating peptide contained anti-gelatinase scFv-LDM fusion protein shows potent antitumor efficacy in pancreatic cancer. Zhong G; Xu Z; Yang R; Zhang S; Li L; Wu M; Liu H; Zhen Y J Cancer; 2018; 9(4):674-682. PubMed ID: 29556325 [TBL] [Abstract][Full Text] [Related]
42. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma. Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309 [TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675 [TBL] [Abstract][Full Text] [Related]
44. Site-specific PEGylation of lidamycin and its antitumor activity. Li L; Shang B; Hu L; Shao R; Zhen Y Acta Pharm Sin B; 2015 May; 5(3):264-9. PubMed ID: 26579455 [TBL] [Abstract][Full Text] [Related]
45. MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine. Qin Y; Liu XJ; Li L; Liu XJ; Li Y; Gao RJ; Shao RG; Zhen YS Oncol Rep; 2014 Jul; 32(1):121-30. PubMed ID: 24807584 [TBL] [Abstract][Full Text] [Related]
46. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486 [TBL] [Abstract][Full Text] [Related]
47. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase. Fengqiang W; Boyang S; Yongsu Z Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678 [TBL] [Abstract][Full Text] [Related]
48. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity. Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871 [TBL] [Abstract][Full Text] [Related]
49. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. Heuck F; Ellermann J; Borchmann P; Rothe A; Hansen H; Engert A; von Strandmann EP J Immunother; 2004; 27(5):347-53. PubMed ID: 15314543 [TBL] [Abstract][Full Text] [Related]
50. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Chen J; Ouyang ZG; Zhang SH; Zhen YS Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403 [TBL] [Abstract][Full Text] [Related]
51. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11]. Wang FQ; Shang BY; Zhen YS Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796 [TBL] [Abstract][Full Text] [Related]
52. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment. Rinaldi I Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526 [TBL] [Abstract][Full Text] [Related]
53. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation. Tao HY; He SM; Zhao CY; Wang Y; Sheng WJ; Zhen YS Int J Biol Macromol; 2023 Jan; 226():1088-1099. PubMed ID: 36435475 [TBL] [Abstract][Full Text] [Related]
54. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461 [TBL] [Abstract][Full Text] [Related]
55. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. Huang YH; Shang BY; Zhen YS World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019 [TBL] [Abstract][Full Text] [Related]